Immunic, Inc..
IMUX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Immunic, Inc. is a biopharmaceutical company focused on developing orally administered, small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. Their pipeline includes drug candidates targeting diseases like relapsing-remitting multiple sclerosis (RRMS), progressi...Show More
Better Health for All
-30
Immunic, Inc. is entirely devoted to developing therapies for chronic inflammatory and autoimmune diseases, with 100% of its pipeline focused on health improvement. Clinical trials for vidofludimus calcium in multiple sclerosis show statistically significant disability improvement and low rates of worsening, while IMU-856 shows positive effects in celiac disease, indicating exceptional health benefits.
1
The company maintains an outstanding safety record, with vidofludimus calcium showing a favorable safety and tolerability profile over 5.5 years and no new safety signals in trials involving approximately 2,700 individuals.
2
IMU-856 also demonstrated safety and tolerability in its Phase 1b trial, with no serious adverse events.
3
The company's products target significant global health burdens, such as MS affecting over 2.8 million people worldwide and celiac disease affecting 1 in 100 people, demonstrating a substantial reach to vulnerable populations.
4
However, the company's patent protection for vidofludimus calcium extends into 2041, which could limit access.
5
The company's R&D expenses were $80.0 million in 2024 and $83.2 million in 2023, but without total revenue, the percentage allocated to health innovation cannot be determined.
6
The company provides health and wellness programs for its 91 employees, including mental health support.
7
Immunic also engages in health education through R&D days and conference presentations.
8
The company enrolled the first patient in an investigator-sponsored Phase 2 clinical trial for Post COVID Syndrome, indicating a structured crisis response.
9
The company's annual report contains forward-looking statements with known and unknown risks, and the auditor's opinion includes an explanatory paragraph about substantial doubt regarding its ability to continue as a going concern, indicating some risk transparency issues.
10
The company is required to disclose material cybersecurity incidents, but no specific data protection practices are detailed.
11
Fair Money & Economic Opportunity
0
Immunic, Inc. is a biopharmaceutical company focused on developing therapies for chronic inflammatory and autoimmune diseases.
1
The company's core business does not involve offering lending, insurance, or deposit services to consumers.
2
Consequently, the provided articles do not contain specific, concrete data points relevant to the KPIs under the 'Fair Money & Economic Opportunity' value, which are designed for financial institutions. Therefore, all KPIs are omitted due to a lack of applicable evidence within the scope of financial services.
Fair Pay & Worker Respect
40
In 2022, the CEO's total compensation was 9.0 times the median employee's total compensation.
1
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The articles either explicitly state that no information was found for the relevant metrics, or they contain general company information (such as employee numbers or internal code of conduct details) that does not directly address supplier-related ethical sourcing practices, certifications, audits, or spend percentages. For example, while a Code of Conduct mentions prompt investigation of violations and non-discrimination in supplier selection, it does not provide quantifiable data for remediation speed, ethical clause coverage in supplier contracts, or supplier diversity spend.
1
Honest & Fair Business
-40
Immunic, Inc. has a formal whistleblower protection policy that includes a commitment to no retaliation and allows for anonymous reporting of suspected violations of its Insider Trading Policy to outside counsel.
1
The Audit Committee Charter, adopted July 2, 2020, also details the committee's role in receiving and addressing complaints.
2
The company is subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, and has a written Code of Business Conduct and Ethics that applies to all directors, officers, and employees.
3
Its Audit Committee Charter also details the committee's role in reviewing Foreign Corrupt Practices Act compliance.
4
However, there is no evidence of training frequency or effectiveness metrics for the anti-corruption policy.
Kind to Animals
-70
Immunic, Inc. conducts animal studies as part of its preclinical testing for drug development, with efficacy observed in several animal disease models.
1
These studies are performed according to regulations, including German Regulations for Animal Welfare, and require approval from authorized ethics committees.
2
Preclinical trials must also comply with FDA, EMA, and ICH guidelines, including Good Laboratory Practice.
3
For specific efficacy studies, groups of 6 or 7 mice were used, and rat pharmacokinetics were also performed.
4
There is no evidence that Immunic, Inc. employs validated non-animal testing methods. While the FDA is working to reduce and replace animal testing, including launching a pilot program for non-animal-based testing strategies and anticipating thousands of animals could be spared, this is a regulatory initiative and not evidence of Immunic's current practices.
5
Immunic's animal studies are conducted according to regulations, but there is no evidence of a formal policy beyond compliance or any engagement in collaborative initiatives for animal-free testing or policy advocacy.
No War, No Weapons
0
Immunic, Inc. is a biopharmaceutical company focused on developing oral therapies for chronic inflammatory and autoimmune diseases.
1
Its products, Vidofludimus Calcium and IMU-856, are designed for therapeutic use in autoimmune and gastrointestinal diseases, explicitly stated as not for military or weapons applications.
2
The company's core business does not involve defense or arms-related activities, nor does it develop dual-use products with military applications.
3
There is no evidence of the company having any defense-related assets to divest, or engaging in peace technology investment.
4
The company's business model does not involve mineral inputs or procurement from conflict zones, and no ethical red lines related to weapons are applicable.
5
Therefore, several KPIs are scored as N/A, indicating no involvement in such activities.
Planet-Friendly Business
0
The provided articles contain no specific, concrete data points or metrics relevant to any of the 'Planet-Friendly Business' KPIs.
1
Multiple articles explicitly state that sustainability data is unavailable or that no environmental, social, or governance (ESG) metrics are present.
2
Therefore, no assessment can be made against the defined KPIs.
Respect for Cultures & Communities
0
No specific, quantitative evidence was found in the provided articles to assess Immunic, Inc. against any of the KPIs for 'Respect for Cultures & Communities'. The articles either discuss general topics related to indigenous rights and community development without mentioning Immunic, Inc., or they are job postings and company career pages that do not provide relevant metrics for these specific KPIs.
1
Safe & Smart Tech
0
The company states it uses state-of-the-art encryption methods, such as SSL via HTTPS, for data transmission.
1
Its privacy policy outlines that users have rights to information, correction, deletion, restriction, objection, and data portability.
2
The company also states that data is deleted when no longer needed, unless legally required to be retained.
3
Immunic, Inc. emphasizes compliance with GDPR, BDSG-n.F., and other applicable data protection regulations.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Immunic, Inc. on Zero Waste & Sustainable Products.